Page 1 | Search Results | Cancer Immunology Research | American Association for Cancer Research

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Abstract PR04: CRISPR-mediated PTPN2 deletion in CAR T cells enhances anti-tumor efficacy

Xin Du, Florian Wiede, Phillip K. Darcy, Tony Tiganis

Cancer Immunol Res (2022) 10 (1_Supplement): PR04.

https://doi.org/10.1158/2326-6074.TUMIMM21-PR04

Published: 01 January 2022

View article titled, Abstract PR04: CRISPR-mediated PTPN2 deletion in CAR T cells enhances anti-tumor efficacy

Journal Articles

Abstract PR06: Dual-specific T-cells and an indirect vaccine eradicate large solid tumors

Clare Y. Slaney, Bianca von Scheidt, Phillip K. Darcy, Michael H. Kershaw

Cancer Immunol Res (2019) 7 (2_Supplement): PR06.

https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-PR06

Published: 01 February 2019

View article titled, Abstract PR06: Dual-specific T-cells and an indirect vaccine eradicate large solid tumors

Journal Articles

Antagonism of IAPs Enhances CAR T-cell Efficacy

Jessica Michie, Paul A. Beavis, Andrew J. Freeman, Stephin J. Vervoort, Kelly M. Ramsbottom, Vignesh Narasimhan, Emily J. Lelliott, Najoua Lalaoui, Robert G. Ramsay, Ricky W. Johnstone, John Silke, Phillip K. Darcy, Ilia Voskoboinik, Conor J. Kearney, Jane Oliaro

Cancer Immunol Res (2019) 7 (2): 183–192.

https://doi.org/10.1158/2326-6066.CIR-18-0428

Published: 01 February 2019

View article titled, Antagonism of IAPs Enhances CAR T-cell Efficacy

Includes: Multimedia, Supplementary data

Journal Articles

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4⁺Foxp3⁻ Cell–Mediated Modulation of CD103⁺ Dendritic Cells

Paul A. Beavis, Melissa A. Henderson, Lauren Giuffrida, Alexander J. Davenport, Emma V. Petley, Imran G. House, Junyun Lai, Kevin Sek, Nicole Milenkovski, Liza B. John, Sherly Mardiana, Clare Y. Slaney, Joseph A. Trapani, Sherene Loi, Michael H. Kershaw, Nicole M. Haynes, Phillip K. Darcy

Cancer Immunol Res (2018) 6 (9): 1069–1081.

https://doi.org/10.1158/2326-6066.CIR-18-0291

Published: 04 September 2018

View article titled, Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3− Cell–Mediated Modulation of CD103+ Dendritic Cells

Includes: Supplementary data

Journal Articles

Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

Natasha K. Brockwell, Katie L. Owen, Damien Zanker, Alex Spurling, Jai Rautela, Hendrika M. Duivenvoorden, Nikola Baschuk, Franco Caramia, Sherene Loi, Phillip K. Darcy, Elgene Lim, Belinda S. Parker

Cancer Immunol Res (2017) 5 (10): 871–884.

https://doi.org/10.1158/2326-6066.CIR-17-0150

Published: 01 October 2017

View article titled, Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

Includes: Supplementary data

Journal Articles

Abstract A104: Eradication of large solid tumors in immunocompetent mice using dual specific CAR T cells and vaccination

Clare Y. Slaney, Jennifer A. Westwood, Paul A. Beavis, Phillip K. Darcy, Michael H. Kershaw

Cancer Immunol Res (2016) 4 (1_Supplement): A104.

https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-A104

Published: 03 January 2016

View article titled, Abstract A104: Eradication of large solid tumors in immunocompetent mice using dual specific CAR T cells and vaccination

Journal Articles

Abstract B10: Individual CAR-T cells, when activated via their CAR or TCR, kill tumor cells with similar kinetics and can kill multiple sequential tumor targets

Alex J. Davenport, Misty R. Jenkins, Ryan S. Cross, S Yong Carmen, H Miles Prince, David S. Ritchie, Joseph A. Trapani, Michael H. Kershaw, Phillip K. Darcy, Paul J. Neeson

Cancer Immunol Res (2015) 3 (10_Supplement): B10.

https://doi.org/10.1158/2326-6074.TUMIMM14-B10

Published: 09 October 2015

View article titled, Abstract B10: Individual CAR-T cells, when activated via their CAR or TCR, kill tumor cells with similar kinetics and can kill multiple sequential tumor targets

Journal Articles

CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells

Alexander J. Davenport, Misty R. Jenkins, Ryan S. Cross, Carmen S. Yong, H. Miles Prince, David S. Ritchie, Joseph A. Trapani, Michael H. Kershaw, Phillip K. Darcy, Paul J. Neeson

Cancer Immunol Res (2015) 3 (5): 483–494.

https://doi.org/10.1158/2326-6066.CIR-15-0048

Published: 03 May 2015

View article titled, CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells

Includes: Multimedia, Supplementary data

Journal Articles

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

Paul A. Beavis, Nicole Milenkovski, Melissa A. Henderson, Liza B. John, Bertrand Allard, Sherene Loi, Michael H. Kershaw, John Stagg, Phillip K. Darcy

Cancer Immunol Res (2015) 3 (5): 506–517.

https://doi.org/10.1158/2326-6066.CIR-14-0211

Published: 03 May 2015

View article titled, Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

Includes: Supplementary data

NARROW

Abstract PR04: CRISPR-mediated PTPN2 deletion in CAR T cells enhances anti-tumor efficacy

Abstract PR06: Dual-specific T-cells and an indirect vaccine eradicate large solid tumors

Antagonism of IAPs Enhances CAR T-cell Efficacy

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4⁺Foxp3⁻ Cell–Mediated Modulation of CD103⁺ Dendritic Cells

Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

Abstract A104: Eradication of large solid tumors in immunocompetent mice using dual specific CAR T cells and vaccination

Abstract B10: Individual CAR-T cells, when activated via their CAR or TCR, kill tumor cells with similar kinetics and can kill multiple sequential tumor targets

CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only